Novel therapeutic approach: Ligands for PPARγ and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells

Breast Cancer Research and Treatment

Volumn 74, Issue 2, 2002, Pages 155-165

  Elstner, E ^a   Williamson, E A ^b   Zang, C ^a   Fritz, J ^a   Heber, D ^c   Fenner, M ^a   Possinger, K ^a   Koeffler, H P ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; bcl 2; Breast cancer cells; In vitro; PPAR ; RAR RXR; Retinoids; Troglitazone

Indexed keywords

BAG 1 PROTEIN; BRCA1 PROTEIN; ESTROGEN RECEPTOR ALPHA; LG 10069; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN; PROTEIN BCL 2; PROTEIN P53; RETINOID X RECEPTOR; TROGLITAZONE; UNCLASSIFIED DRUG; CELL RECEPTOR; DNA BINDING PROTEIN; NUCLEAR PROTEIN; REPRESSOR PROTEIN; RETINOIC ACID RECEPTOR; TRANSCRIPTION FACTOR; ZINC FINGER PROTEIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CLONOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; GENETIC DISORDER; HUMAN; HUMAN CELL; LIGAND BINDING; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOSYNTHESIS; BREAST TUMOR; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETICS; MICROBODY; PATHOLOGY; PHYSIOLOGY;

APOPTOSIS; BREAST NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; HUMAN; LIGANDS; MICROBODIES; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, RETINOIC ACID; REPRESSOR PROTEINS; SUPPORT, NON-U.S. GOV'T; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; ZINC FINGERS; HUMANS;

EID: 0035990751     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016114026769     Document Type: Article

References (79)

1. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid)
2. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients
3. Treatment of first relapse of acute promyelocytic leukemia with all-trans retinoic acid
4. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck
5. 13-cis-retinoic acid plus interferon alpha-2a: Highly active systemic therapy for squamous cell carcinoma of the cervix
6. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor
7. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice
8. Dietary fat and fiber in relation to risk of breast cancer. An 8-year follow-up
9. Ras may mediate mammary cancer promotion by high fat
10. Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells
11. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells
12. A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GM7845, inhibits rat mammary carcinogenesis
13. A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions
14. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo
15. Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells
16. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor γ in non-small cell lung cancer
17. Differentiation and reversal of malignant changes in colon cancer through PPARgamma
18. Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells
19. Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor γ, and retinoids
20. Thiazolidinedione induces apoptosis and monocytic differentiation in the promyelocytic leukemia cell line HL60
21. Combination of a potent 20-epi-vitamin D3 analogue (KH1060) with 9-cis retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression and induces apoptosis in HL-60 leukemic cells
22. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma-1 and gamma-2
23. Synergistic decrease of clonal proliferation, induction of differentiation, and apoptosis of acute promyelocytic leukemia cells after combined treatment with novel 20-epi vitamin D3 analogs and 9-cis retinoic acid
24. 20-epi-vitamin D3 analogues: A novel class of potent inhibitors of proliferation and inducer of differentiation of human breast cancer cell lines
25. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-12,14-prostaglandin J2
26. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
27. Correlation of retinoid binding affinity to retinoic acid receptor alpha with retinoid inhibition of growth of estrogen receptor-positive MCF-7 mammary carcinoma cells
28. Inhibition of human mammary carcinoma cell proliferation by retinoids and intracellular cAMP-elevating compounds
29. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor
30. Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages
31. p57Kip2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene
32. Cloning of p27kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals
33. Role of the cyclin-dependent kinase inhibitors in the development of cancer
34. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer
35. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients
36. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas
37. Decrease expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression
38. Growth retardation and tumor inhibition by BRCA1
39. Risk of cancer in BRCA1-mutation carriers
40. Breast and ovarian cancer incidence in BRCA1-mutation carriers
41. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews
42. BRCA-associated breast cancer: Absence of a characteristic immunophenotype
43. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
44. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
45. Steroid hormone receptor phosphorylation: Is there a physiologic role?
46. Inhibition of breast cancer cell growth in vitro by tyrosine kinase inhibitor
47. Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines
48. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells
49. MCF breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and a reduced estrogen-dependence and tamoxifen-sensitivity in vivo
50. Estrogen-dependent, tamoxifen-resistent tumorigenic growth of MCF-7 cells transfected with HER2/neu
51. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
52. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group Study
53. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein
54. c-erbB 2 expression predicts tamoxifen efficacy in breast cancer patients
55. Analysis of bcl-2 in sporadic breast carcinoma
56. Bcl-2 expression in the spectrum of preinvasive breast lesions
57. Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer
58. Clinical significance of bcl-2 gene expression in human breast cancer tissues
59. Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma
60. Loss of Bcl-2 in invasive breast cancer is associated with high rate of cell death, but also with increased proliferative activity
61. Bcl-2 protein expression and long-term survival in breast cancer
62. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy
63. The expression of Ki-S1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer
64. Expression of bcl-2 protein predicts efficacy of adjuvant treatment in operable node-positive breast cancer
65. Bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group Study
66. Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation
67. The role of bcl2 expression in breast carcinomas
68. Cloning and functional analysis of BAG-1: A novel Bcl-2 binding protein with anti-cell death activity
69. A protein that interacts with members of the nuclear hormone receptor family: Identification and cDNA cloning
70. BAG-1L protein enhances androgen receptor function
71. RAP46 is a negative regulator of glucocorticoid receptor action and hormone-induced apoptosis
72. Expression of multiple apoptosis-regulatory genes in human breast cancer cell lines and primary tumors
73. Differential expression of antiapoptotic gene BAG-1 in human breast normal and cancer cell lines and tissues
74. Bag-1: A novel biomarker predicting long-term survival in early stage breast cancer
75. The cellular protein p53 in human tumours
76. P53 in breast cancer
77. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo
78. Down-regulation of bcl-2 by p53 in breast cancer cells